UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 18, 2008
ALKERMES, INC.
(Exact Name of Registrant as Specified in its Charter)
| |
|
|
|
|
PENNSYLVANIA
(State or Other Jurisdiction of Incorporation)
|
|
1-14131
(Commission
File Number)
|
|
23-2472830
(I.R.S. Employer
Identification No.) |
| |
|
|
|
|
| |
88 Sidney Street |
|
|
|
| |
Cambridge, Massachusetts
|
|
02139 |
|
| |
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (617) 494-0171
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 7.01
Regulation FD Disclosure
On
April 18, 2008, Alkermes, Inc. (“Alkermes”) orally
confirmed to Indevus Pharmaceuticals, Inc. and then reconfirmed on
April 28, 2008 in writing that
the Feasibility Agreement dated as of February 4, 2005, which related to the
development of an inhaled formulation of trospium chloride (“ALKS 27”) for the treatment of chronic
obstructive pulmonary disease, had terminated in accordance with its
terms.
All patent rights related to ALKS 27 are owned by Alkermes.
Alkermes intends to independently
continue the development and commercialization of an inhaled trospium product based on its
proprietary AIR® pulmonary technology.